Skip to main content

Market Overview

Health Catalyst Reports Fourth Quarter and Year End 2020 Results

Share:

SOUTH JORDAN, Utah, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ((", Health Catalyst, ", NASDAQ:HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported financial results for the quarter and year ended December 31, 2020.

"In the fourth quarter of 2020, I am pleased to share that we achieved strong performance across our business, including exceeding the mid-point of our quarterly and full-year guidance for both revenue and Adjusted EBITDA," said Dan Burton, CEO of Health Catalyst. "While 2020 represented an extremely challenging year across the healthcare ecosystem, I am proud of the part Health Catalyst played in supporting our customers to ensure they successfully managed through this unprecedented time. In particular, I am pleased with the role that our data and analytics technology played in enabling our customers' response to the pandemic, as evidenced by the significant increase in our technology usage throughout 2020. In this spirit, we were pleased to receive the news that our Chargemaster Management product, a new revenue analytics product addition through the Vitalware acquisition, was recently ranked as Best in KLAS for 2020. This marks the third year in a row that the Vital-CDM product has achieved this distinction from the KLAS organization."

Financial Highlights for the Three and Twelve Months Ended December 31, 2020

Key Financial Metrics

  Three Months Ended December 31,   Year over Year Change   Twelve Months Ended
December 31,
  Year over Year Change
  2020   2019       2020       2019    
                           
GAAP Financial Data: (in thousands, except percentages)    (in thousands, except percentages)
Technology revenue $ 32,317     $ 22,582     43%   $ 110,467     $ 83,975     32%
Professional services revenue $ 20,962     $ 20,919     —%   $ 78,378     $ 70,966     10%
Total revenue $ 53,279     $ 43,501     22%   $ 188,845     $ 154,941     22%
Loss from operations $ (38,922 )   $ (13,672 )   (185)%   $ (96,125 )   $ (54,865 )   (75)%
Net loss $ (43,018 )   $ (14,266 )   (202)%   $ (115,017 )   $ (60,096 )   (91)%
Other Non-GAAP Financial Data:(1)                      
Adjusted Technology Gross Profit $ 22,089     $ 15,393     44%   $ 75,666     $ 56,378     34%
Adjusted Technology Gross Margin 68 %   68 %         68 %     67 %    
Adjusted Professional Services Gross Profit $ 5,734     $ 6,877     (17)%   $ 19,358     $ 24,494     (21)%
Adjusted Professional Services Gross Margin 27 %   33 %         25 %     35 %    
Total Adjusted Gross Profit $ 27,823     $ 22,270     25%   $ 95,024     $ 80,872     17%
Total Adjusted Gross Margin 52 %   51 %         50 %     52 %    
Adjusted EBITDA $ (4,694 )   $ (6,488 )   28%   $ (21,287 )   $ (27,363 )   22%

________________________
(1) These measures are not calculated in accordance with generally accepted accounting principles in the United States (GAAP). See the accompanying "Non-GAAP Financial Measures" section below for more information about these financial measures, including the limitations of such measures, and for a reconciliation of each measure to the most directly comparable measure calculated in accordance with GAAP.

Other Key Metrics

  As of December 31,
  2020   2019   2018
DOS Subscription Customers 74     65     50  
           
  Year Ended December 31,
  2020   2019   2018
Dollar-based Retention Rate 102 %   109 %   107 %

Given our high level of technology revenue predictability, we realized minimal impact on our technology dollar-based retention as a result of COVID-19, however, the financial strain imposed by COVID-19 on a number of our customers has led to a meaningfully lower professional services dollar-based retention in 2020, and thus a lower total Dollar-based Retention Rate, compared to what we have achieved historically.

Financial Outlook

Health Catalyst provides forward-looking guidance on total revenue, a GAAP measure, and Adjusted EBITDA, a non-GAAP measure.

For the first quarter of 2021, we expect:

  • Total revenue between $53.0 million and $56.0 million, and
  • Adjusted EBITDA between $(3.9) million and $(1.9) million

For the full year of 2021, we expect:

  • Total revenue between $225.1 million and $228.1 million, and
  • Adjusted EBITDA between $(16.0) million and $(13.5) million

We have not reconciled guidance for Adjusted EBITDA to net loss, the most directly comparable GAAP measure, and have not provided forward-looking guidance for net loss, because there are items that may impact net loss, including stock-based compensation, that are not within our control or cannot be reasonably predicted.

Chair of the Board Transition

The Board of Directors (the "Board") of Health Catalyst appointed Timothy G. Ferris, MD, as Chair of the Board effective March 1, 2021. Dr. Ferris has served as a member of Health Catalyst's Board of Directors since January 2018.

Since 2017, Dr. Ferris has served as the Chief Executive Officer of the Massachusetts General Physicians Organization, a multi-specialty medical group. Prior to that, he was the Senior Vice President for Population Health at Partners Healthcare and Massachusetts General Hospital, from 2011 to 2017. Dr. Ferris holds a B.A. from Middlebury College, an M.Phil. from Wolfson College, Oxford University, an M.D. from Harvard Medical School, and an M.P.H. from Harvard School of Public Health.

Dan Burton, CEO of Health Catalyst said, "I am grateful for Dr. Ferris' alignment to our mission, our cultural attributes, and our operating principles. I anticipate that Dr. Ferris' unique perspective will continue to add significant insights and ideas during this next phase of our company's journey as he helps us increasingly appreciate the most significant challenges facing healthcare organizations."

Dr. Ferris said he is honored to have been named Chair of Health Catalyst's Board. "The company's mission-orientation, culture, and commitment to team members and clients are refreshing and drive meaningful and innovative healthcare improvements. I look forward to contributing to the vision for ongoing transformative technological solutions that improve data-informed decision-making for the healthcare ecosystem," said Dr. Ferris.

Dr. Ferris was appointed as Chair to succeed Fraser Bullock, who joined the Board as an observer of Health Catalyst in 2012 and has served as Chair since 2014. Bullock will continue to serve on the Board at least through the completion of his current term in June 2022.

"We want to express our deep gratitude to Fraser for his significant contributions to the company over the past seven years in his role as Chair. His leadership has been instrumental in guiding our growth and development, and we're grateful to continue to benefit from his insights and experience as a board member," Burton said.

Quarterly Conference Call Details

The company will host a conference call to review the results today, Thursday, February 25, 2021 at 5:00 p.m. E.T. The conference call can be accessed by dialing 1-877-295-1104 for U.S. participants, or 1-470-495-9486 for international participants, and referencing participant code 3180522. A live audio webcast will be available online at https://ir.healthcatalyst.com/. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.

About Health Catalyst

Health Catalyst is a leading provider of data and analytics technology and services to healthcare organizations committed to being the catalyst for massive, measurable, data-informed healthcare improvement. Its customers leverage the cloud-based data platform—powered by data from more than 100 million patient records and encompassing trillions of facts—as well as its analytics software and professional services expertise to make data-informed decisions and realize measurable clinical, financial, and operational improvements. Health Catalyst envisions a future in which all healthcare decisions are data informed.

Available Information

Health Catalyst intends to use its Investor Relations website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements include statements regarding our future growth and our financial outlook for Q1 and fiscal year 2021. Forward-looking statements are subject to risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. Actual results may differ materially from the results predicted, and reported results should not be considered as an indication of future performance.

Important risks and uncertainties that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) changes in laws and regulations applicable to our business model; (ii) changes in market or industry conditions, regulatory environment and receptivity to our technology and services; (iii) results of litigation or a security incident; (iv) the loss of one or more key customers or partners; (v) the impact of COVID-19 on our business and results of operations; and (vi) changes to our abilities to recruit and retain qualified team members. For a detailed discussion of the risk factors that could affect our actual results, please refer to the risk factors identified in our SEC reports, including, but not limited to the Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2020 that was filed with the SEC on November 10, 2020 and the Annual Report on Form 10-K for the year ended December 31, 2020 expected to be filed with the SEC on or about February 25, 2021. All information provided in this release and in the attachments is as of the date hereof, and we undertake no duty to update or revise this information unless required by law.


Condensed Consolidated Balance Sheets
(in thousands, except share and per share data, unaudited)

  As of December 31,
  2020   2019
Assets      
Current assets:      
Cash and cash equivalents         $ 91,954     $ 18,032  
Short-term investments         178,917     210,245  
Accounts receivable, net         48,296     27,570  
Prepaid expenses and other assets         10,632     8,392  
Total current assets         329,799     264,239  
Property and equipment, net         12,863     4,295  
Intangible assets, net         98,921     25,535  
Operating lease right-of-use assets         24,729     3,787  
Goodwill         107,822     3,694  
Other assets         3,606     810  
Total assets         $ 577,740     $ 302,360  
Liabilities and stockholders' equity      
Current liabilities:      
Accounts payable         $ 5,332     $ 3,622  
Accrued liabilities         16,510     8,944  
Acquisition-related consideration payable         2,000     2,192  
Deferred revenue         47,145     30,653  
Operating lease liabilities         2,622     2,806  
Contingent consideration liabilities         14,427      
Total current liabilities         88,036     48,217  
Long-term debt, net of current portion         168,994     48,200  
Acquisition-related consideration payable, net of current portion             1,860  
Deferred revenue, net of current portion         1,878     1,459  
Operating lease liabilities, net of current portion         23,669     1,654  
Contingent consideration liabilities, net of current portion         16,837      
Other liabilities         2,227     326  
Total liabilities         301,641     101,716  
Commitments and contingencies      
Stockholders' equity:      
Common stock, $0.001 par value; 43,376,848 and 36,678,854 shares issued and outstanding as of December 31, 2020 and December 31, 2019, respectively         43     37  
Additional paid-in capital         1,001,645     811,049  
Accumulated deficit         (725,650 )   (610,514 )
Accumulated other comprehensive income         61     72  
Total stockholders' equity         276,099     200,644  
Total liabilities and stockholders' equity         $ 577,740     $ 302,360  


Condensed Consolidated Statements of Operations
(in thousands, except per share data, unaudited)

  Three Months Ended
December 31,
  Twelve Months Ended
December 31,
  2020   2019   2020   2019
Revenue:              
Technology         $ 32,317     $ 22,582     $ 110,467     $ 83,975  
Professional services         20,962     20,919     78,378     70,966  
Total revenue         53,279     43,501     188,845     154,941  
Cost of revenue, excluding depreciation and amortization:              
Technology(1)         10,456     7,261     35,604     27,797  
Professional services(1)(3)         16,072     14,416     62,473     47,548  
Total cost of revenue, excluding depreciation and amortization         26,528     21,677     98,077     75,345  
Operating expenses:              
Sales and marketing(1)(3)         14,793     11,705     55,411     47,284  
Research and development(1)(3)         14,978     13,043     53,517     46,252  
General and administrative(1)(2)(4)(5)         28,129     8,380     59,240     31,713  
Depreciation and amortization         7,773     2,368     18,725     9,212  
Total operating expenses         65,673     35,496     186,893     134,461  
Loss from operations         (38,922 )   (13,672 )   (96,125 )   (54,865 )
Loss on extinguishment of debt                 (8,514 )   (1,670 )
Interest and other expense, net         (4,072 )   (495 )   (11,572 )   (3,419 )
Loss before income taxes         (42,994 )   (14,167 )   (116,211 )   (59,954 )
Income tax provision (benefit)         24     99     (1,194 )   142  
Net loss         $ (43,018 )   $ (14,266 )   $ (115,017 )   $ (60,096 )
Less: accretion of redeemable convertible preferred stock                     180,826  
Net loss attributable to common stockholders         $ (43,018 )   $ (14,266 )   $ (115,017 )   $ (240,922 )
Net loss per share attributable to common stockholders, basic and diluted         $ (1.01 )   $ (0.39 )   $ (2.91 )   $ (12.86 )
Weighted-average shares outstanding used in calculating net loss per share attributable to common stockholders, basic and diluted         42,589     36,519     39,541     18,741  
               
Adjusted net loss(6)         $ (6,687 )   $ (7,791 )   $ (26,797 )   $ (33,806 )
Pro forma adjusted net loss per share, basic and diluted(6)         $ (0.16 )   $ (0.21 )   $ (0.68 )   $ (0.93 )
Pro forma as adjusted weighted-average number of shares outstanding used in calculating Adjusted Net Loss per share, basic and diluted(6)         42,589     36,519     39,541     36,268  

_______________
(1) Includes stock-based compensation expense as follows:

  Three Months Ended
December 31,
  Twelve Months Ended
December 31,
  2020   2019   2020   2019
               
Stock-Based Compensation Expense: (in thousands)   (in thousands)
Cost of revenue, excluding depreciation and amortization:              
Technology         $ 228     $ 72     $ 803     $ 200  
Professional services         844     374     3,453     968  
Sales and marketing         3,369     1,173     13,093     3,811  
Research and development         2,082     1,339     8,069     4,841  
General and administrative         4,151     1,858     12,539     8,024  
Total         $ 10,674     $ 4,816     $ 37,957     $ 17,844  

(2) Includes acquisition transaction costs as follows:

  Three Months Ended
December 31,
  Twelve Months Ended
December 31,
  2020   2019   2020   2019
               
Acquisition transaction costs: (in thousands)   (in thousands)
General and administrative         $     $     $ 2,670     $  

(3) Includes post-acquisition restructuring costs as follows:

  Three Months Ended
December 31,
  Twelve Months Ended
December 31,
  2020   2019   2020   2019
Post-Acquisition Restructuring Costs: (in thousands)   (in thousands)
Cost of revenue, excluding depreciation and amortization:              
Professional services         $     $     $     $ 108  
Sales and marketing                     306  
Research and development                     32  
Total         $     $     $     $ 446  

(4) Includes the change in fair value of contingent consideration liabilities, as follows:

  Three Months Ended
December 31,
  Twelve Months Ended
December 31,
  2020   2019   2020   2019
               
Change in fair value of contingent consideration liabilities: (in thousands)   (in thousands)
General and administrative         $ 15,092     $     $ 14,088     $  

(5) Includes duplicate headquarters rent expense, as follows:

  Three Months Ended
December 31,
  Twelve Months Ended
December 31,
  2020   2019   2020   2019
               
Duplicate Headquarters Rent Expense: (in thousands)   (in thousands)
General and administrative         $ 689     $     $ 1,398     $  

(6) Includes pro forma adjustments to net loss attributable to common stockholders and the weighted average number of common shares outstanding directly attributable to the closing of our initial public offering on July 29, 2019 as well as certain other non-GAAP adjustments. Refer to the "Non-GAAP Financial Measures—Pro Forma Adjusted Net Loss Per Share" section below for further details.


Condensed Consolidated Statements of Cash Flows
(in thousands, unaudited)

  Twelve Months Ended
December 31,
Cash flows from operating activities 2020   2019
Net loss $ (115,017 )   $ (60,096 )
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation and amortization 18,725     9,212  
Loss on extinguishment of debt 8,514     1,670  
Amortization of debt discount and issuance costs 8,054     1,081  
Non-cash operating lease expense 4,303     3,460  
Investment discount and premium amortization 1,349     (615 )
Provision for expected credit losses 863      
Stock-based compensation expense 37,957     17,844  
Deferred tax (benefit) provision (1,273 )   40  
Change in fair value of contingent consideration liabilities 14,088      
Other 116     (54 )
Change in operating assets and liabilities:      
Accounts receivable, net (16,448 )   127  
Prepaid expenses and other assets (3,667 )   (1,596 )
Accounts payable, accrued liabilities, and other liabilities 8,243     (86 )
Deferred revenue 11,459     77  
Operating lease liabilities (3,414 )   (3,248 )
Net cash used in operating activities (26,148 )   (32,184 )
       
Cash flows from investing activities      
Purchase of short-term investments (189,526 )   (256,007 )
Proceeds from the sale and maturity of short-term investments 219,069     50,677  
Acquisition of businesses, net of cash acquired (101,657 )    
Purchase of property and equipment (7,775 )   (2,015 )
Capitalization of internal use software (1,442 )   (384 )
Purchase of intangible assets (1,248 )   (1,935 )
Proceeds from sale of property and equipment 14     62  
Net cash used in investing activities (82,565 )   (209,602 )
       
Cash flows from financing activities      
Proceeds from convertible note securities, net of issuance costs 222,482      
Purchase of capped calls concurrent with issuance of convertible senior notes (21,743 )    
Proceeds from credit facilities, net of debt issuance costs     47,169  
Repayment of credit facilities (57,043 )   (21,821 )
Proceeds from exercise of stock options 36,264     2,656  
Proceeds from employee stock purchase plan 4,273     2,978  
Payments of acquisition-related consideration (1,624 )   (1,713 )
Proceeds from initial public offering, net of underwriters' discounts and commissions     194,649  
Proceeds from the issuance of redeemable convertible preferred stock, net of issuance costs     12,073  
Payments of deferred offering costs     (4,610 )
Net cash provided by financing activities 182,609     231,381  
Effect of exchange rate on cash and cash equivalents 26     6  
Net increase (decrease) in cash and cash equivalents 73,922     (10,399 )
       
Cash and cash equivalents at beginning of period 18,032     28,431  
Cash and cash equivalents at end of period $ 91,954     $ 18,032  

Non-GAAP Financial Measures

To supplement our financial information presented in accordance with GAAP, we believe certain non-GAAP measures, including Adjusted Gross Profit, Adjusted Gross Margin, Adjusted EBITDA, Adjusted Net Loss, and Adjusted Net Loss per share, basic and diluted, are useful in evaluating our operating performance. We use this non-GAAP financial information to evaluate our ongoing operations, as a component in determining employee bonus compensation, and for internal planning and forecasting purposes. We believe that non-GAAP financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. In addition, other companies, including companies in our industry, may calculate similarly-titled non-GAAP measures differently or may use other measures to evaluate their performance. A reconciliation is provided below for each non-GAAP financial measure to the most directly comparable financial measure stated in accordance with GAAP. Investors are encouraged to review the related GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures, and not to rely on any single financial measure to evaluate our business.

Adjusted Gross Profit and Adjusted Gross Margin

Adjusted Gross Profit is a non-GAAP financial measure that we define as revenue less cost of revenue, excluding depreciation and amortization and excluding (i) stock-based compensation and (ii) post-acquisition restructuring costs. We define Adjusted Gross Margin as our Adjusted Gross Profit divided by our revenue. We believe Adjusted Gross Profit and Adjusted Gross Margin are useful to investors as they eliminate the impact of certain non-cash expenses and allow a direct comparison of these measures between periods without the impact of non-cash expenses and certain other non-recurring operating expenses. The following is a reconciliation of revenue, the most directly comparable GAAP financial measure, to Adjusted Gross Profit, for the three and twelve months ended December 31, 2020 and 2019:

  Three Months Ended December 31, 2020
  (in thousands, except percentages)
  Technology   Professional
Services
  Total
Revenue         $ 32,317     $ 20,962     $ 53,279  
Cost of revenue, excluding depreciation and amortization         (10,456 )   (16,072 )   (26,528 )
Gross profit, excluding depreciation and amortization         21,861     4,890     26,751  
Add:          
Stock-based compensation         228     844     1,072  
Adjusted Gross Profit         $ 22,089     $ 5,734     $ 27,823  
Gross margin, excluding depreciation and amortization         68 %   23 %   50 %
Adjusted Gross Margin         68 %   27 %   52 %


  Three Months Ended December 31, 2019
  (in thousands, except percentages)
  Technology   Professional
Services
  Total
Revenue         $ 22,582     $ 20,919     $ 43,501  
Cost of revenue, excluding depreciation and amortization         (7,261 )   (14,416 )   (21,677 )
Gross profit, excluding depreciation and amortization         15,321     6,503     21,824  
Add:          
Stock-based compensation         72     374     446  
Adjusted Gross Profit         $ 15,393     $ 6,877     $ 22,270  
Gross margin, excluding depreciation and amortization         68 %   31 %   50 %
Adjusted Gross Margin         68 %   33 %   51 %


  Twelve Months Ended December 31, 2020
  (in thousands, except percentages)
  Technology   Professional
Services
  Total
Revenue         $ 110,467     $ 78,378     $ 188,845  
Cost of revenue, excluding depreciation and amortization         (35,604 )   (62,473 )   (98,077 )
Gross profit, excluding depreciation and amortization         74,863     15,905     90,768  
Add:          
Stock-based compensation         803     3,453     4,256  
Adjusted Gross Profit         $ 75,666     $ 19,358     $ 95,024  
Gross margin, excluding depreciation and amortization         68 %   20 %   48 %
Adjusted Gross Margin         68 %   25 %   50 %


  Twelve Months Ended December 31, 2019
  (in thousands, except percentages)
  Technology   Professional
Services
  Total
Revenue         $ 83,975     $ 70,966     $ 154,941  
Cost of revenue, excluding depreciation and amortization         (27,797 )   (47,548 )   (75,345 )
Gross profit, excluding depreciation and amortization         56,178     23,418     79,596  
Add:          
Stock-based compensation         200     968     1,168  
Post-acquisition restructuring costs                 108       108  
Adjusted Gross Profit         $ 56,378     $ 24,494     $ 80,872  
Gross margin, excluding depreciation and amortization         67 %   33 %   51 %
Adjusted Gross Margin         67 %   35 %   52 %

Adjusted EBITDA

Adjusted EBITDA is a non-GAAP financial measure that we define as net loss adjusted for (i) interest and other expense, net, (ii) loss on extinguishment of debt, (iii) income tax (benefit) provision, (iv) depreciation and amortization, (v) stock-based compensation, (vi) acquisition transaction costs, (vii) change in fair value of contingent consideration liabilities, (viii) duplicate headquarters rent expense, and (ix) post-acquisition restructuring costs when they are incurred. We believe Adjusted EBITDA provides investors with useful information on period-to-period performance as evaluated by management and comparison with our past financial performance and is useful in evaluating our operating performance compared to that of other companies in our industry, as this metric generally eliminates the effects of certain items that may vary from company to company for reasons unrelated to overall operating performance. The following is a reconciliation of our net loss, the most directly comparable GAAP financial measure, to Adjusted EBITDA, for the three and twelve months ended December 31, 2020 and 2019:

  Three Months Ended
December 31,
  Twelve Months Ended
December 31,
  2020   2019   2020   2019
               
  (in thousands)   (in thousands)
Net loss $ (43,018 )   $ (14,266 )   $ (115,017 )   $ (60,096 )
Add:              
Interest and other expense, net 4,072     495     11,572     3,419  
Loss on extinguishment of debt         8,514     1,670  
Income tax (benefit) provision 24     99     (1,194 )   142  
Depreciation and amortization 7,773     2,368     18,725     9,212  
Stock-based compensation 10,674     4,816     37,957     17,844  
Acquisition transaction costs         2,670      
Change in fair value of contingent consideration liabilities 15,092         14,088      
Duplicate headquarters rent expense 689         1,398      
Post-acquisition restructuring costs                     446  
Adjusted EBITDA $ (4,694 )   $ (6,488 )   $ (21,287 )   $ (27,363 )

Pro Forma Adjusted Net Loss Per Share

Adjusted Net Loss is a non-GAAP financial measure that we define as net loss attributable to common stockholders adjusted for (i) accretion of redeemable convertible preferred stock, (ii) stock-based compensation, (iii) amortization of acquired intangibles, (iv) loss on debt extinguishment, (v) acquisition transaction costs, (vi) change in fair value of contingent consideration liabilities, (vii) non-cash interest expense related to our convertible senior notes, (viii) duplicate headquarters rent expense, and (ix) post-acquisition restructuring costs. We believe Adjusted Net Loss provides investors with useful information on period-to-period performance as evaluated by management and comparison with our past financial performance and is useful in evaluating our operating performance compared to that of other companies in our industry, as this metric generally eliminates the effects of certain items that may vary from company to company for reasons unrelated to overall operating performance.

On July 29, 2019, we closed our initial public offering (our IPO) in which we issued and sold 8,050,000 shares (inclusive of the underwriters' option to purchase an additional 1,050,000 shares) of common stock at $26.00 per share. We received net proceeds of $194.6 million after deducting underwriting discounts and commissions and before deducting offering costs of $4.6 million. Upon the closing of our IPO, all shares of our outstanding redeemable convertible preferred stock converted into 23,151,481 shares of common stock on a one-for-one basis. We have prepared the below adjusted condensed consolidated statement of operations data to present pro forma adjusted net loss per share amounts that will be comparable between the current and prior periods presented as if the conversion of all outstanding shares of redeemable convertible preferred stock and the issuance of the IPO shares had occurred as of the beginning of the prior year comparative periods.

  Three Months Ended December 31,   Twelve Months Ended December 31,
  2020   2019   2020   2019
               
Numerator: (in thousands, except share and per share amounts)
Net loss attributable to common stockholders $ (43,018 )   $ (14,266 )   $ (115,017 )   $ (240,922 )
Add:              
Accretion of redeemable convertible preferred stock             180,826  
Stock-based compensation 10,674     4,816     37,957     17,844  
Amortization of acquired intangibles 7,082     1,659     15,868     6,330  
Loss on extinguishment of debt         8,514     1,670  
Acquisition transaction costs         2,670      
Change in fair value of contingent consideration liability 15,092         14,088      
Non-cash interest expense related to convertible senior notes 2,794         7,725      
Duplicate headquarters rent expense 689         1,398      
Post-acquisition restructuring costs             446  
Adjusted Net Loss $ (6,687 )   $ (7,791 )   $ (26,797 )   $ (33,806 )
Denominator:              
Weighted-average number of shares used in calculating net loss per share attributable to common stockholders, basic and diluted 42,588,839     36,519,401     39,540,726     18,741,119  
Pro forma adjustments:              
Pro forma adjustment to reflect issuance and conversion of redeemable convertible preferred stock to common stock, assuming the conversion took place as of the beginning of the 2019 period             13,002,887  
Pro forma adjustment to reflect issuance of shares of common stock as part of IPO, assuming the issuance took place as of the beginning of the 2019 period             4,524,110  
Pro forma as adjusted weighted-average number of shares used in calculating Adjusted Net Loss per share, basic and diluted 42,588,839     36,519,401     39,540,726     36,268,116  
Pro forma adjusted net loss per share, basic and diluted $ (0.16 )   $ (0.21 )   $ (0.68 )   $ (0.93 )

Health Catalyst Investor Relations Contact:
Adam Brown
Senior Vice President, Investor Relations and FP&A
+1 (855)-309-6800
ir@healthcatalyst.com 

Health Catalyst Media Contact:
Amanda Hundt
amanda.hundt@healthcatalyst.com 
+1 (575) 491-0974


Primary Logo

View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com